Indications and uses
Epinephrine Injection is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis in adult and pediatric patients who weigh 15 kg or greater.
Epinephrine Injection is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis in adult and pediatric patients who weigh 15 kg or greater.
Recommended dosage for patients who weigh 15 kg or greater is based on weight and the dosage is provided in Table 1. Administer Epinephrine Injection intramuscularly or subcutaneously into the anterolateral aspect of the thigh. Table 1 Recommended Dosage of Epinephrine Injection Based on Patient’s Weight Patient’s Weight Dosage 30 kg or greater 0.3 mg 15 kg to less than 30 kg 0.15 mg Since the doses of e...
How Supplied Epinephrine Injection is a clear and colorless solution for intramuscular or subcutaneous use. Epinephrine Injection is available as an auto-injector as described in Table 2. Table 2 Epinephrine Injection Auto-injector Package Configurations and Strengths Strength Package Configuration NDC 0.3 mg/0.3 mL Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes ...
Epinephrine Injection is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis in adult and pediatric patients who weigh 15 kg or greater.
Recommended dosage for patients who weigh 15 kg or greater is based on weight and the dosage is provided in Table 1. Administer Epinephrine Injection intramuscularly or subcutaneously into the anterolateral aspect of the thigh.
Table 1 Recommended Dosage of Epinephrine Injection Based on Patient’s Weight
Patient’s Weight | Dosage |
30 kg or greater | 0.3 mg |
15 kg to less than 30 kg | 0.15 mg |
Injection:
None.
Epinephrine Injection should only be injected into the anterolateral aspect of the thigh [see Dosage and Administration (2.2)].
Do not inject intravenously
Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to a sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine for this inadvertent administration.
Do not inject into buttock
Injection into the buttock may not provide effective treatment of anaphylaxis. If Epinephrine Injection is injected into the buttock, advise the patient to administer a second dose of Epinephrine Injection into the anterolateral aspect of the thigh if symptoms worsen or persist, and then go immediately to the nearest emergency room for further treatment of anaphylaxis. Additionally, injection into the buttock has been associated with the development of Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower the risk.
Do not inject into digits, hands or feet
Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area and may not provide effective treatment of anaphylaxis. Advise the patient to administer a second dose of Epinephrine Injection into the anterolateral aspect of the thigh if experiencing anaphylaxis, and then go immediately to the nearest emergency room and inform the healthcare provider in the emergency room of the location of the accidental injection. Treatment of such inadvertent administration should consist of vasodilation, in addition to further appropriate treatment of anaphylaxis [see Adverse Reactions (6)].
Hold leg firmly during injection
To minimize the risk of injection related injury when administering Epinephrine Injection to young children or infants, instruct caregivers to hold the child’s leg firmly in place and limit movement prior to and during injection.
Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Clostridium spores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill Clostridium spores. To decrease the risk of Clostridium infection, do not inject Epinephrine Injection into the buttock [see Warnings and Precautions (5.1)]. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site.
Some patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, it should be recognized that the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, instruct patients with these conditions, and/or caregivers to the circumstances under which epinephrine should be used.
Administer epinephrine with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias [see Adverse Reactions (6) and Drug Interactions (7)].
Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in
patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment.
Administer epinephrine with caution in patients with these conditions, including elderly patients and pregnant women.
Epinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though Epinephrine Injection contains sodium bisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite in Epinephrine Injection should not deter administration of the drug for treatment of serious allergic or other emergency situations.
The following clinically significant adverse reactions are described elsewhere in the labeling:
The following adverse reactions associated with the use of epinephrine were identified in observational trials, case reports, studies, or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular: angina, arrhythmias (including fatal ventricular fibrillation), cerebral hemorrhage, hypertension, pallor, palpitations, tachyarrhythmia, tachycardia, vasoconstriction, ventricular ectopy, and stress cardiomyopathy
Gastrointestinal Disorders: nausea and vomiting
Infections: Clostridial infections (gas gangrene)
Metabolism and Nutrition Disorders: transient hyperglycemia, sweating
Neurological: disorientation, impaired memory, panic, psychomotor agitation, sleepiness,
tingling, weakness, tremor, hypoesthesia, dizziness, headache
Psychiatric: anxiety, apprehensiveness, restlessness
Respiratory: respiratory difficulties
Skin and Subcutaneous Tissue Disorders: bruising, bleeding, discoloration, erythema, necrotizing fasciitis, myonecrosis
Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.3) and Adverse Reactions (6)].
The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine, and catechol-O-methyl transferase (COMT) inhibitors such as entacapone.
The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol.
The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine.
Ergot alkaloids may also reverse the pressor effects of epinephrine.
Risk Summary
Prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with anaphylaxis, and treatment with epinephrine should not be delayed (see Clinical Considerations). In animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis was teratogenic at doses 7 times and higher than the maximum recommended human intramuscular and subcutaneous dose on a mg/m2 basis (see Data).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Disease-Associated Maternal and Embryo/Fetal Risk:
During pregnancy, anaphylaxis can be catastrophic and can lead to hypoxic-ischemic encephalopathy and permanent central nervous system damage or death in the mother and, more commonly, in the fetus or neonate. Treatment of anaphylaxis during pregnancy should not be delayed.
Data
Animal Data
In an embryofetal development study with rabbits dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including gastroschisis and embryonic lethality) at doses approximately 40 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days).
In an embryofetal development study with mice dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including embryonic lethality) at doses approximately 8 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 4 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days).
In an embryofetal development study with hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine was shown to be teratogenic at doses approximately 7 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day).
Risk Summary
There is no information on the presence of epinephrine in human milk, the effects on the breastfed infants, or the effects on milk production. However, due to its poor oral bioavailability and short half-life, transfer of epinephrine into breastmilk is expected to be low. Treatment of anaphylaxis in breastfeeding patients should not be delayed.
The safety and effectiveness of Epinephrine Injection for the emergency treatment of type I allergic reactions, including anaphylaxis have been established in pediatric patients who weigh 15 kg or greater. The use of Epinephrine Injection for this indication is supported by clinical experience. Clinical experience with the use of epinephrine suggests that the adverse reactions seen in pediatric patients are similar in nature and extent to those both expected and reported in adults. Since the doses of epinephrine delivered from Epinephrine Injection are fixed, use other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary.
The safety and effectiveness of Epinephrine Injection have not been established in pediatric patients who weigh less than 15 kg.
Clinical studies of Epinephrine Injection for emergency treatment of type I allergic reactions, including anaphylaxis, were not conducted in geriatric patients aged 65 and over to determine whether they respond differently from younger adult patients. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, these patients may be at greater risk for developing adverse reactions after epinephrine administration.
Overdosage of epinephrine has been reported to produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients. Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation.
Epinephrine overdosage can also cause transient bradycardia followed by tachycardia which may be accompanied by fatal cardiac arrhythmias; premature ventricular contractions followed by multifocal ventricular tachycardia; atrial tachycardia and occasionally by atrioventricular block; extreme pallor and coldness of the skin; metabolic acidosis; kidney failure.
Epinephrine is rapidly inactivated in the body and treatment following overdosage with epinephrine is primarily supportive. Treatment of epinephrine associated pulmonary edema consists of a rapidly acting alpha-adrenergic blocking drug (such as phentolamine mesylate) and respiratory support. Treatment of epinephrine associated arrhythmias consists of administration of a beta-adrenergic blocking drug (such as propranolol). If necessary, pressor effects may be counteracted by rapidly acting vasodilators or α-adrenergic blocking drugs. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug.
Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
Epinephrine Injection, USP 0.3 mg and 0.15 mg, are single-dose auto-injectors and combination products containing drug and device components.
Each Epinephrine Injection, USP 0.3 mg, delivers a single dose of 0.3 mg epinephrine from Epinephrine Injection, USP (0.3 mL) in a sterile solution.
Each Epinephrine Injection, USP 0.15 mg, delivers a single dose of 0.15 mg epinephrine from Epinephrine Injection, USP (0.15 mL) in a sterile solution.
Epinephrine Injection, USP 0.3 mg and Epinephrine Injection, USP 0.15 mg each contain 1.1 mL of epinephrine solution. 0.3 mL and 0.15 mL epinephrine solution are dispensed for Epinephrine Injection, USP 0.3 mg and Epinephrine Injection, USP 0.15 mg, respectively, when activated. The solution remaining after activation is not available for future use and should be discarded.
Each 0.3 mL in Epinephrine Injection, USP 0.3 mg, contains 0.3 mg epinephrine, 2.6 mg sodium chloride, not more than 1.5 mg chlorobutanol, 0.45 mg sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, and water for injection. The pH range is 2.2-5.0.
Each 0.15 mL in Epinephrine Injection, USP 0.15 mg, contains 0.15 mg epinephrine, 1.3 mg sodium chloride, not more than 0.75 mg chlorobutanol, 0.225 mg sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, and water for injection. The pH range is 2.2-5.0.
Epinephrine is a sympathomimetic catecholamine. Chemically, epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl]benzyl alcohol with the following structure:

Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin. Replace Epinephrine Injection, USP if the epinephrine solution appears discolored (pinkish or brown color), cloudy, or contains particles.
Epinephrine acts on both alpha- and beta-adrenergic receptors.
Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension.
Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis.
Epinephrine also alleviates pruritus, urticaria, and angioedema, and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.
When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted.
Epinephrine and other catecholamines have been shown to have mutagenic potential in vitro. Epinephrine was positive in the Salmonella bacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the in vivo micronucleus assay. Epinephrine is an oxidative mutagen based on the E. coli WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine where indicated [see Indications and Usage (1)].
The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (40-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.
How Supplied
Epinephrine Injection is a clear and colorless solution for intramuscular or subcutaneous use. Epinephrine Injection is available as an auto-injector as described in Table 2.
Table 2 Epinephrine Injection Auto-injector Package Configurations and Strengths
Strength | Package Configuration | NDC |
0.3 mg/0.3 mL | Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes | NDC 0115-1694-49 |
Auto-injector in carrier tube | NDC 0115-1694-30 | |
0.15 mg/0.15 mL | Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes | NDC 0115-1695-49 |
Auto-injector in carrier tube | NDC 0115-1695-30 |
Storage and Handling
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Administration
For additional video instructions on the use of epinephrine injection,go to
www.epinephrineautoinject.com.
Injection-Related Complications
Advise patients to seek immediate medical care in the case of accidental injection into the digits, hands or feet because such an accidental injection to these areas may cause loss of blood flow to the affected area [see Warnings and Precautions (5.1)].
Serious Infections at the Injection Site
Advise patients that rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following injection of epinephrine for anaphylaxis. Instruct patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the Epinephrine Injection site [see Warnings and Precautions (5.2)].
Risks Associated with Certain Coexisting Conditions
Advise patients with coexisting conditions (cardiac arrhythmia and ischemia, coronary artery disease, hypertension, pulmonary edema, hyperthyroidism, renal impairment, Parkinson's disease, diabetes), for increased risks that may be associated with use of epinephrine [see Warnings and Precautions (5.3)].
Storage and Handling
Epinephrine Injection is light sensitive and should be stored in the individual carrier tube provided to protect it from light. The individual carrier tube is not waterproof. Instruct patients that Epinephrine Injection must be properly disposed of once the blue end caps have been removed or after use [see How Supplied/Storage and Handling (16)].
Manufactured for and Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807
© 2025 Amneal Pharmaceuticals LLC. All rights reserved.
For inquiries call 1-877-835-5472
1871-05
Rev. 03-2026-05
PATIENT INFORMATION EPINEPHRINE injection (ep″ i nef′ rin), for intramuscular or subcutaneous use Epinephrine Injection USP, 0.3 mg Each Epinephrine Injection USP, 0.3 mg delivers a single dose of 0.3 mg epinephrine USP, in 0.3 mL (0.3 mg/0.3 mL) Epinephrine Injection USP, 0.15 mg Each Epinephrine Injection USP, 0.15 mg delivers a single dose of 0.15 mg epinephrine USP, in 0.15 mL (0.15 mg/0.15 mL) For allergic emergencies (anaphylaxis) |
Read this Patient Information leaflet carefully before you use Epinephrine Injection and each time you get a refill. There may be new information. You, your parent, caregiver, or others who may be able to administer Epinephrine Injection should know how to use it before you have an allergic emergency. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. |
What is the most important information I should know aboutEpinephrine Injection? 1. Epinephrine Injection is a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening and can happen within minutes. If untreated, anaphylaxis can lead to death. Allergic emergencies may be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes. Symptoms of anaphylaxis may include:
2. It is recommended that people are prescribed and have immediate access to 2 Epinephrine Injection devices at all times. Sometimes a single dose of epinephrine may not be enough to treat a serious allergic reaction before seeking emergency medical help. You should also have immediate access to 2 Epinephrine Injection devices in case the first device is activated before the dose can be given. A device that has been activated accidentally cannot be used to treat an allergic emergency (anaphylaxis). Note: Epinephrine Injection has been activated if you see the needle sticking out of the red needle end and the viewing window is blocked. You may not know when an allergic emergency (anaphylaxis) will happen. Talk to your healthcare provider if you need additional Epinephrine Injection devices to keep at work, school, or other locations. If you use 1 Epinephrine Injection device to treat an emergency allergic reaction, be sure to replace it so you always have immediate access to 2 devices. Tell your family members, caregivers, and others where you keep your Epinephrine Injection. Make sure they know how to use it before you need it. You may be unable to speak in an allergic emergency. 3. When you have an allergic emergency (anaphylaxis) use Epinephrine Injection right away. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed, after using Epinephrine Injection. Before you receive Epinephrine Injection, your healthcare provider should talk to you about when to get emergency help. If symptoms do not improve or if they worsen after the first dose, or you accidentally inject Epinephrine Injection intothe fingers, toes, hands or feet, a second dose of Epinephrine Injection may be administered with a second auto-injector starting 5 minutes after the first dose. If more than 2 doses are needed for an allergic emergency, they must be given by a healthcare provider. |
What isEpinephrine Injection?
|
What should I tell my healthcare provider before using Epinephrine Injection? Before you use Epinephrine Injection, tell your healthcare provider about all your medical conditions. Your healthcare provider may give you more instructions about when and how to use your Epinephrine Injection if you have the following:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Also tell your healthcare provider about all known allergies. Some medicines may increase or decrease the effects of epinephrine, and epinephrine may affect how other medicines work. Know the medicines you take. Keep a list of all your medicines, including over-the-counter medicines, vitamins and herbal supplements to show your healthcare provider and pharmacist when you get a new medicine. Use your Epinephrine Injection for treatment of anaphylaxis as prescribed by your healthcare provider, regardless of your medical conditions or the medicine you take. |
How should I useEpinephrine Injection?
|
What are the possible side effects ofEpinephrine Injection? Epinephrine Injection may cause serious side effects. Injection-related complications
Serious infections at the injection site
Common side effects of Epinephrine Injection include:
These side effects may go away with rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Epinephrine Injection. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Amneal Pharmaceuticals LLC at 1-877-835-5472. |
How should I storeEpinephrine Injection?
When your sharps disposal container is almost full, follow your community guidelines for proper disposal. There may be state or local laws about how you should dispose of used needles and syringes. For more information about safe sharps disposal, visit the FDA website at |
General information about the safe and effective use of Epinephrine Injection: Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Epinephrine Injection for a condition for which it was not prescribed. Do not give Epinephrine Injection to other people. This Patient Information leaflet summarizes the most important information about Epinephrine Injection. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about Epinephrine Injection that is written for health professionals. For more information and video instructions on the use of Epinephrine Injection, go to |
What are the ingredients inEpinephrine Injection? Active Ingredient: epinephrine Inactive Ingredients: sodium chloride, chlorobutanol, sodium bisulfite, hydrochloric acid, sodium hydroxide, and water. |
Important Information
|
Incorrect Use and Correct Use of Epinephrine Injection
Incorrect Use | Correct Use and Important Reminders |
Storing Epinephrine Injection outside the carrier tube. | Always keep Epinephrine Injection stored in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof. |
Storing of the Epinephrine Injection outside of the recommended storage conditions. | Always keep your Epinephrine Injection stored at room temperature (68°F to 77°F / 20°C to 25°C). |
Failing to remove the Epinephrine Injection from the carrier tube before use. | Remove Epinephrine Injection from the carrier tube before use. |
Failing to remove both the blue caps in proper sequence before use. | Before use, remove the blue needle shield cap first to expose the red needle end. Then remove the blue end cap. |
Failing to remove both blue caps before use. | Epinephrine Injection will not activate or deliver the dose if both blue caps are not removed. |
Failing to remove the blue caps in the proper order. | Removing the blue caps in the incorrect order may cause premature activation of Epinephrine Injection. |
Failing to remove the blue needle shield cap properly, resulting in the needle sheath remaining in place. | Pull off the blue needle shield cap by grasping the ribbed area and pulling straight off until the red needle end is visible. Do not squeeze the non-ribbed area. |
Activating Epinephrine Injection upside down, resulting in injection into the hand. | The needle exits from the red needle end, which must be placed against the middle of the outer thigh (upper leg) at a 90˚ angle (perpendicular) before and during activation. |
Failing to apply enough force to activate Epinephrine Injection. | Press down hard and hold Epinephrine Injection firmly against the outer thigh at a 90˚ angle for 10 seconds. Do not swing or jab the device. |
Expecting an audible click to confirm activation. | You may or may not hear a sound when the injection starts. |
Assuming the dose was not delivered because liquid remains in the device. | It is normal for most of the medicine to remain in the auto-injector after the dose is delivered. The dose has been delivered if the needle is visible after use. |
Administering at an injection site other than the outer thigh. | Inject Epinephrine Injection only into the middle of the outer thigh (upper leg). |
Removing the device at an angle, causing needle bending. | Place the red needle end against the thigh at a 90° angle (perpendicular), press down firmly, and remove the device straight out at a 90° angle after injection. |
Failing to hold Epinephrine Injection in place long enough. | Hold Epinephrine Injection firmly in place for a full 10 seconds to ensure dose delivery. |
Failing to locate the expiration date. | Remove Epinephrine Injection from the carrier tube. The expiration date is located on the auto-injector label. |
For more information and video instructions on the use of Epinephrine Injection, go to
www.epinephrineautoinject.com or call 1-877-835-5472.
This Patient Information has been approved by the U.S. Food and Drug Administration Rev. 03/2026
EPINEPHRINE injection (ep″ i nef′ rin),
for intramuscular or subcutaneous use
Epinephrine Injection USP, 0.3 mg
Each Epinephrine Injection USP, 0.3 mg delivers a single dose of 0.3 mg epinephrine USP in 0.3 mL (0.3 mg/0.3 mL)
Epinephrine Injection USP, 0.15 mg
Each Epinephrine Injection USP, 0.15 mg delivers a single dose of 0.15 mg epinephrine USP in 0.15 mL (0.15 mg/0.15 mL)
For allergic emergencies (anaphylaxis)
This Instructions for Use contains information on how to properly administer Epinephrine Injection.
Your Epinephrine Injection

Figure A. Epinephrine Injection, USP 0.3 mg (yellow label) and
Epinephrine Injection, USP 0.15 mg (orange label), showing the auto-injector and carrier tube components
Important Information You Need to Know Before Administering Epinephrine Injection

Figure B. Inject Epinephrine Injection into the middle of the outer thigh (upper leg)
Each Epinephrine Injection is for single use only.
The dose has been delivered if you see the needle sticking out of the red needle end after use. It is normal for most of the medicine to remain in the auto-injector after the dose is injected.

Figure C. Correct way to hold the Epinephrine Injection with red needle end pointing down
Preparing to Inject Epinephrine Injection
Read the following information while preparing to inject Epinephrine Injection:
Make sure Epinephrine Injection has not been used.
Epinephrine Injection has already been used if:
Preparing to Inject a Child

Figure D. Pull off the blue needle shield cap first and then the blue end cap
Checking the Solution Color
Examine the solution in the viewing window of your Epinephrine Injection regularly. See the information below:

Figure E. Solution Viewing Window
How to check the Solution Color:
Solution Appearance
✓ Use Epinephrine Injection if the solution is clear and colorless.
X Do not use the Epinephrine Injection if the solution is discolored (pinkish or brown color), cloudy, or contains solid particles. Throw away (dispose of it) and use a new Epinephrine Injection (see “Disposing of an Expired, Unused or Used Epinephrine Injection” on the Patient Information).
Injecting Epinephrine Injection
Step 1. Remove Epinephrine Injection from the carrier tube. See Figure F.
Figure F
Step 2. Pull off the blue needle shield cap first by grasping at the ribbed area and pulling. You will now see a red needle end. Then pull off the blue end cap. See Figure G.
Important:

Figure G
Step 3. Inject the Epinephrine Injection
Self Administration (see Figure H) or Caregiver Administration (see Figure I)
Figure H – Self Administration
Figure I – Caregiver Administration
Step 4. Remove the Auto-Injector
Pull Epinephrine Injection straight out at a 90° angle(perpendicular)from the outer thigh (upper leg).
Step 5. Get emergency medical help if needed.
Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed, after using Epinephrine Injection. Before you receive Epinephrine Injection, your healthcare provider should talk to you about when to get emergency medical help.
Step 6. After use
Warning: After Epinephrine Injection is activated, the needle does not retract back into the device.
After use, carefully place the used Epinephrine Injectionback into the carrier tube to cover the needle.
Figure J
Figure K
StoringEpinephrine Injection
Disposing of Epinephrine Injection
Important: The blue needle shield cap and blue end cap are small parts and may pose a choking hazard for children. Throw away the blue needle shield cap and blue end cap immediately after using Epinephrine Injection.
For more information and video instructions on the use of Epinephrine Injection, visit
www.epinephrineautoinject.com or call 1-877-835-5472.
© 2025 Amneal Pharmaceuticals LLC. All rights reserved.
Manufactured for and Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807
1872-06
This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised 03/2026
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1870225 | EPINEPHrine (generic for Adrenaclick) 0.15 MG in 0.15 ML Auto-Injector | PSN | 16 |
| 1870230 | EPINEPHrine (generic for Adrenaclick) 0.3 MG in 0.3 ML Auto-Injector | PSN | 16 |
| 1870225 | NDA020800 0.15 ML epinephrine 1 MG/ML Auto-Injector | SCD | 16 |
| 1870230 | NDA020800 0.3 ML epinephrine 1 MG/ML Auto-Injector | SCD | 16 |
| 1870225 | epinephrine (generic for Adrenaclick) 0.15 MG per 0.15 ML Auto-Injector | SY | 16 |
| 1870230 | epinephrine (generic for Adrenaclick) 0.3 MG per 0.3 ML Auto-Injector | SY | 16 |
| Class | Version | Type | Effective |
|---|---|---|---|
| EPINEPHRINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | Data Matrix | (01)50312345678901(21)123456789012(17)201231(10)123456L | GTIN-14: 50312345678901 GTIN storage (14 digits): 50312345678901 | epinephrine-injection-14.jpg, epinephrine-injection-16.jpg |
| Barcode | EAN-13 | 0301151694491 | GTIN-13: 0301151694491 EAN-13: 0301151694491 GTIN-12: 301151694491 UPC-A: 301151694491 GTIN storage (14 digits): 00301151694491 | epinephrine-injection-16.jpg |
| Barcode | EAN-13 | 0301151695498 | GTIN-13: 0301151695498 EAN-13: 0301151695498 GTIN-12: 301151695498 UPC-A: 301151695498 GTIN storage (14 digits): 00301151695498 | epinephrine-injection-14.jpg |
| QR code link | QR Code | epinephrine-injection-14.jpg, epinephrine-injection-16.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 0b4ec9ca-d305-43fc-88dd-7a510313efe0 | Product name | 1 | 20260105 |
| bb209f42-a85f-4fee-9d3d-c9dded168625 | Product name | 1 | 20251208 |
| 49628fc7-2031-4c28-bd31-0ef3aa8f44a3 | Product name | 3 | 20251118 |
| cbf85893-59ef-423f-87d4-a573c000a8b9 | Product name | 8 | 20250731 |
| b5b1095b-40cd-8a9e-b111-502545045b07 | Product name | 4 | 20250325 |
| e190029e-423b-473c-8e04-2ada59b5b711 | Product name | 1 | 20250314 |
| e0031c74-3853-42bc-8e10-86dbbe83992e | Product name | 2 | 20231116 |
| f7046b89-2016-499a-adc6-78479172abc6 | Product name | 1 | 20230425 |
| 2686d634-e712-4007-8dbf-3d37c6c4d71f | Product name | 1 | 20181121 |
| fa8b5901-e681-426f-82fe-54f6d81ec698 | Product name | 4 | 20180619 |
| bd49bb86-2d32-4a7a-a594-eeda2e29af42 | Product name | 1 | 20180118 |
| c08ab52f-2fc8-4409-9d9f-ed8edc0bd070 | Product name | 1 | 20171221 |
| 3becbe78-12d9-4ad2-9b4c-1e36f8d1303a | Product name | 1 | 20170815 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0115-1694-30 | epinephrine | 1 in 1 CARTON | INJECTION | 1 | 16 | |
| 0115-1694-30 | epinephrine | 1 in 1 CASE | INJECTION | 1 | 16 | |
| 0115-1694-49 | epinephrine | 2 in 1 CARTON | INJECTION | 2 | 16 | |
| 0115-1694-49 | epinephrine | 1 in 1 CASE | INJECTION | 1 | 16 | |
| 0115-1695-30 | epinephrine | 1 in 1 CARTON | INJECTION | 1 | 16 | |
| 0115-1695-30 | epinephrine | 1 in 1 CASE | INJECTION | 1 | 16 | |
| 0115-1695-49 | epinephrine | 1 in 1 CASE | INJECTION | 1 | 16 | |
| 0115-1695-49 | epinephrine | 2 in 1 CARTON | INJECTION | 2 | 16 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0115-1695-30 | EA - Each | 0115-1695 | e0a9c949-4fcf-498e-9dc2-331621c120e2 | 1 | 2022-06-06 |
| 0115-1695-49 | EA - Each | 0115-1695 | c510929a-2b38-4ef2-bc28-391f0cb6523c | 1 | 2017-03-06 |
| 0115-1694-30 | EA - Each | 0115-1694 | d7a54aa3-12ed-470a-9854-11cd94591357 | 1 | 2019-06-19 |
| 0115-1694-49 | EA - Each | 0115-1694 | 8f59b63e-d9a0-4426-8607-bce9aae464a2 | 1 | 2017-03-06 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0115-1695 | 0115-1695-30, 0115-1695-49 |
| 0115-1694 | 0115-1694-30, 0115-1694-49 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| EPINEPHRINE | YKH834O4BH | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| CHLOROBUTANOL | HM4YQM8WRC | IACT |
| SODIUM BISULFITE | TZX5469Z6I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| EPINEPHRINE | YKH834O4BH | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| CHLOROBUTANOL | HM4YQM8WRC | IACT |
| SODIUM BISULFITE | TZX5469Z6I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020800-001 | TWINJECT | EPINEPHRINE | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | ||
| N020800-002 | TWINJECT | EPINEPHRINE | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | ||
| N020800-003 | ADRENACLICK | EPINEPHRINE | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 |
| N020800-004 | ADRENACLICK | EPINEPHRINE | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 |
| Application-product | TE code |
|---|---|
| N020800-003 | BX |
| N020800-004 | BX |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N020800-001 | TWINJECT | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N020800-002 | TWINJECT | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N020800-001 | TWINJECT | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N020800-002 | TWINJECT | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N020800-001 | TWINJECT | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N020800-002 | TWINJECT | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020800-001 | TWINJECT | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020800-002 | TWINJECT | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N020800-001 | TWINJECT | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N020800-002 | TWINJECT | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020800-001 | TWINJECT 0.3 | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020800-002 | TWINJECT 0.15 | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020800-001 | TWINJECT 0.3 | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020800-002 | TWINJECT 0.15 | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020800-001 | TWINJECT 0.3 | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020800-002 | TWINJECT 0.15 | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020800-001 | TWINJECT 0.3 | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020800-002 | TWINJECT 0.15 | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020800-001 | TWINJECT 0.3 | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2003-05-30 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020800-002 | TWINJECT 0.15 | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | 2004-05-28 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020800-003 | ADRENACLICK | EQ 0.15MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020800-004 | ADRENACLICK | EQ 0.3MG/DELIVERY | INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2009-11-25 | 5bbf6a4d5a75… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N020800-003 | BX | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N020800-004 | BX | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N020800-003 | BX | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N020800-004 | BX | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N020800-003 | BX | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N020800-004 | BX | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020800-003 | BX | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020800-004 | BX | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N020800-003 | BX | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N020800-004 | BX | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020800-003 | BX | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020800-004 | BX | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020800-003 | BX | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020800-004 | BX | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020800-003 | BX | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020800-004 | BX | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020800-003 | BX | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020800-004 | BX | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020800-003 | BX | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020800-004 | BX | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020800-003 | BX | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020800-004 | BX | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N020800-003 | BX | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N020800-004 | BX | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020800-003 | BX | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020800-004 | BX | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020800-003 | BX | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020800-004 | BX | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020800-003 | BX | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020800-004 | BX | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N020800-003 | BX | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | N020800-004 | BX | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-003 | BX | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-004 | BX | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N020800-003 | BX | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | N020800-004 | BX | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N020800-003 | BX | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | N020800-004 | BX | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N020800-003 | BX | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N020800-004 | BX | 1 | 74a2ff9319b5… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-001 | 7297136 | 2025-01-18 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-001 | 7621891 | 2025-02-04 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-002 | 7297136 | 2025-01-18 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-002 | 7621891 | 2025-02-04 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-003 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-003 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-004 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020800-004 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020800-001 | 7297136 | 2025-01-18 | Drug product | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N020800-001 | 7621891 | 2025-02-04 | Drug product | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N020800-002 | 7297136 | 2025-01-18 | Drug product | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N020800-002 | 7621891 | 2025-02-04 | Drug product | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N020800-003 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020800-003 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020800-004 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020800-004 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020800-001 | 7297136 | 2025-01-18 | Drug product | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N020800-001 | 7621891 | 2025-02-04 | Drug product | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N020800-002 | 7297136 | 2025-01-18 | Drug product | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N020800-002 | 7621891 | 2025-02-04 | Drug product | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N020800-003 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020800-003 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020800-004 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020800-004 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020800-001 | 7297136 | 2025-01-18 | Drug product | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N020800-001 | 7621891 | 2025-02-04 | Drug product | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N020800-002 | 7297136 | 2025-01-18 | Drug product | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N020800-002 | 7621891 | 2025-02-04 | Drug product | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N020800-003 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020800-004 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020800-001 | 7297136 | 2025-01-18 | Drug product | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N020800-001 | 7621891 | 2025-02-04 | Drug product | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N020800-002 | 7297136 | 2025-01-18 | Drug product | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N020800-002 | 7621891 | 2025-02-04 | Drug product | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N020800-003 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020800-003 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020800-004 | 10166334 | 2025-01-21 | Drug product | 2020-02-11 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020800-004 | 7905352 | 2027-04-12 | Drug product | 2017-06-02 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N020800-001 | 7297136 | 2025-01-18 | Drug product | 782e0a99824c… | ||
| 2021-12-28 21:50 UTC | 2021-12 | N020800-001 | 7621891 | 2025-02-04 | Drug product | 782e0a99824c… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| epinephrine | EPINEPHRINE | Amneal Pharmaceuticals of New York LLC | e13f05f1-7d21-49bb-b8d5-24bf9301c3d7 | 2026-03-20 | Warnings, Adverse reactions | 0115-1694-49 0115-1695-30 0115-1695-49 0115-1694-30 0115-1695 0115-1694 00115169530 00115169449 00115169549 00115169430 fdafd090-bed3-4f16-8ab1-fd1573aa633e e13f05f1-7d21-49bb-b8d5-24bf9301c3d7 |
Adverse event summaries are temporarily unavailable. Other product information remains available.